SCHEMBL4336889

SCHEMBL4336889

NC(=S)N/N=C/c1ccc(COc2ccc(Cl)c(Cl)c2)o1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.61
KMT2A Q03164 7/20 0.61
MAPT P10636 7/20 0.61
MEN1 O00255 6/20 0.61
HPGD P15428 5/20 0.61
NPSR1 Q6W5P4 5/20 0.61
HTT P42858 1/20 0.61
LMNA P02545 5/20 0.54
KDM4E B2RXH2 3/20 0.54
CTSL P07711 1/20 0.52
ALOX12 P18054 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
PKM P14618 1/20 0.49
TYR P14679 1/20 0.48
GAA P10253 1/20 0.47
POLB P06746 1/20 0.46
EYA2 O00167 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4336892 1.00 ALDH1A1 (0.61) ALDH1A1KMT2AMAPTMEN1HPGD
SCHEMBL4330782 0.90 ALDH1A1 (0.53) ALDH1A1KMT2AMAPTMEN1HPGD
SCHEMBL4330786 0.90 ALDH1A1 (0.53) ALDH1A1KMT2AMAPTMEN1HPGD
SCHEMBL4332722 0.87 MAPT (0.50) ALDH1A1KMT2AMAPTMEN1HPGD
SCHEMBL13612327 0.87 MAPT (0.50) ALDH1A1KMT2AMAPTMEN1HPGD
SCHEMBL4336786 0.83 SMN1; SMN2 (0.62) ALDH1A1KMT2AMAPTCTSLSMN1; SMN2
SCHEMBL4336780 0.83 SMN1; SMN2 (0.62) ALDH1A1KMT2AMAPTCTSLSMN1; SMN2
SCHEMBL4332719 0.81 MAPT (0.39) ALDH1A1KMT2AMAPTMEN1HPGD
SCHEMBL4326572 0.80 MAPT (0.56) ALDH1A1KMT2AMAPTMEN1HPGD
SCHEMBL4331625 0.80 MAPT (0.54) ALDH1A1KMT2AMAPTMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 ALDH1A1 1459/4885KMT2A 3988/4885MAPT 3619/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 ALDH1A1 1173/4885KMT2A 3714/4885MAPT 3876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.